Saturday 17 October 2026
Export JSPR’s income statement to Excel — free account
Jasper Therapeutics, Inc.
JSPR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.3% and free cash flow grew 55.7%, each against the same quarter a year earlier.
0.48
0.05
−9.43%
Follow JSPR
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 94.50 | 70.30 | 3.86 | 4.00 | 6.41 | 1.39 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 104.60 | 188.80 | 81.22 | 38.00 | 31.01 | 22.52 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 25 | 35 | 45 | 64 | 22 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | 0 | (32) | (31) | (38) | (64) | (71) | (76) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | 0 | 0 | (31) | (38) | (64) | (71) | (76) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | 0.01 | (51.70) | (26.90) | (10.30) | (6.18) | (4.89) | (3.95) | |||||
| Cash flow | — | — | — | (1.47) | 0.00 | (29.56) | (12.57) | (4.99) | (4.29) | (4.03) | |||||
| Capex | — | — | — | 0.00 | 0.00 | (2.13) | (0.16) | (0.03) | (0.04) | 0.00 | |||||
| Free cash flow | — | — | — | (1.47) | 0.00 | (31.69) | (12.73) | (5.01) | (4.33) | (4.03) | |||||
| Book value | — | — | — | 20.00 | (57.35) | 61.01 | 9.87 | 7.51 | 4.23 | 0.22 | |||||
| Shares, m | — | — | — | 0 | 1 | 1 | 4 | 10 | 15 | 19 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | 0 | (34) | (46) | (52) | (63) | (77) | ||||
| Capex | — | — | — | — | — | (2) | (1) | 0 | (1) | 0 | |||||
| Free cash flow | — | — | — | 0 | 0 | (36) | (46) | (52) | (63) | (77) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | 17 | 80 | 35 | 77 | 61 | 21 | ||||
| Total debt | — | — | — | — | 2 | 3 | 4 | — | — | — | |||||
| Net debt | — | — | — | (1) | (20) | (85) | (38) | (87) | (72) | (29) | |||||
| Shareholders’ equity | — | — | — | 5 | (35) | 70 | 36 | 78 | 62 | 4 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (50.65) | (52.37) | (53.07) | (90.00) | (81.55) | (131.06) | ||||
| ROIC | — | — | — | (2.25) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | (0.01) | 210.22 | (178.18) | (71.44) | (112.67) | (101.73) | (230.31) | |||||
Negative figures in brackets.
Charts ten years each
Jasper Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma, Inc. | $18.0M | — (loss-making) | — (loss-making) | −90.75% (below 0%: shrinking) | n/m | +32.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NEUP Neuphoria Therapeutics Inc. | $17.9M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| JSPR Jasper Therapeutics, Inc. | $17.7M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | |
| ANEB Anebulo Pharmaceuticals, Inc. | $17.6M | — (loss-making) | — | — | n/m | +6.58% (above 0%: growing) | — | 0.00% | Compare |
| ACGN Aceragen, Inc. | $17.1M | — (loss-making) | — (loss-making) | +2,394.95% (above 0%: growing) | n/m | −115.67% (below 0%: shrinking) | 100.00% | (834.33%) | Compare |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $17.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| DYAI Dyadic International Inc. | $16.8M | — (loss-making) | — (loss-making) | −0.57% (below 0%: shrinking) | n/m | −1,298.54% (below 0%: shrinking) | (2.39%) | (213.73%) | Compare |
| PBM Psyence Biomedical Ltd. | $16.5M | 0.2× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | Compare |
| TCRX TScan Therapeutics, Inc. | $16.2M | — (loss-making) | — (loss-making) | −65.83% (below 0%: shrinking) | n/m | +18.95% (above 0%: growing) | 100.00% | (2,901.33%) | Compare |
| Median of peers | $17.1M | — | — | −65.83% | — | −54.54% | 100.00% | 0.00% |
Jasper Therapeutics, Inc. (JSPR) key facts
- Jasper Therapeutics, Inc. (JSPR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, JSPR traded at $0.48, a market capitalization of $17.7 million.
- Return on equity was −230.3% and debt-to-equity 0.00.